ACRO Biomedical is bringing some breakthrough products to BIO-Asia Taiwan, a huge annual event in the biotechnology industry, this year.

Among them, the Collagen Bone Matrix product has not only obtained class II medical device certificate from the Ministry of Health and Welfare and US FDA 510 (k) K212156 certification, and also was awarded the Symbol of National Quality

Proving that ACRO Biomeidcal's technology has its own uniqueness in the field of regenerative medicine.

In addition, ACRO Biomedical is also bringing a new product with the application of hair follicle neogenesis, and will start to promote and introduce it to various medical aesthetic clinics in August after the exhibition, which is expected to benefit patients with problems of hair-loss.

ACRO Biomedical was founded in June 2014 in Kaohsiung, Taiwan, by Dr. Dar-Jen Hsieh and a group of scientists and physicians. ACRO Biomedical develops and produces biomaterial medical devices for human tissue engineering and regenerative medicine (TERM). ACRO Biomedical uses its proprietary supercritical CO₂ extraction technology to remove cells, fat and non-collagenous proteins from animal tissues, while keeping the undiminished collagen scaffold as the biomaterial for high-end medical devices in the medical regenerative field of wound care, orthopedics, dentistry, ophthalmology, aesthetic microsurgery, cardiovascular and neural surgery, etc.